New drug cocktail aims to crush leukemia in newly diagnosed patients
NCT ID NCT07548710
First seen May 09, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study tests a new combination of drugs (sonrotoclax, azacitidine, and other targeted medicines) in 205 adults with newly diagnosed acute myeloid leukemia. The goal is to see if this mix can achieve complete remission and reduce cancer cells to undetectable levels. Participants are grouped based on their genetic mutations and overall health, and the treatment is adjusted for each person.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.